Background
Methods
Treatment
Induction treatment
Stem cell mobilizing therapy
High dose therapy
Consolidation
Diagnosis, response evaluation, disease progression
Indication for ASCT
Treatment response
Classification
Survival
Statistics
Results
Patients ≤ 60 years of age | Patients 61–65 years of age | |
---|---|---|
N (%) | N (%) | |
M-Component | ||
IgG κ | 76 (36,1) | 31 (37,5) |
IgG λ | 24 (11,9) | 11 (13,8) |
IgA κ | 27 (12,0) | 13 15,9) |
IgA λ | 12 (6,6) | 7 (8,3) |
light chain κ | 42 (19,1) | 10 (13,2) |
light chain λ | 16 (7,3) | 5 (6,3) |
non secretory | 13 (6,0) | 2 (2,5) |
biclonal | 2 (1,0) | 0 (0) |
no information | 0 | 2 (2,5) |
Stage Durie&Salmon | ||
IA | 55 (26,4) | 22 (27,1) |
IB | 5 (2,4) | 2 (2,4) |
IIA | 82 (38,9) | 33 (41,0) |
IIB | 16 (7,4) | 4 (5,0) |
IIIA | 40 (18,5) | 17 (21,2) |
IIIB | 14 (6,4) | 3 (3,3) |
Stage ISS | ||
ISS I | 65 (31,0) | 21 (26,3) |
ISS II | 40 (18,5) | 18 (22,6) |
ISS III | 39 (18,1) | 19 (23,8) |
No information*) | 68 (32,4) | 23 (27,3) |
Patients ≥ 60 years of age | Patients 61–65 years of age | |
---|---|---|
N (%) | N (%) | |
Induction treatment | ||
VAD | 90 (42,6) | 32 (39,5) |
Cy/Dex | 120 (56,5) | 49 (60,5) |
Vel/Dex | 2 (0,9) | 0 |
Consolidation | ||
IFN | 38 (17,9) | 10 (12,3) |
Bortezomib | 25 (11,9) | 7 (8,6) |
No consolidation | 149 (70,2) | 64 (79,1) |
Treatment response | ||
Progressive disease | 1 (0,6) | 3 (3,6) |
Stable disease | 7 (3,2) | 1 (1,2) |
Minimal response | 9 (4,2) | 2 (2,4) |
Partial response | 102 (48,1) | 49 (59.0) |
Complete response | 57 (27,2) | 19 (22,9) |
Not evaluable | 36 (16,7) | 9 (10,9) |
Survival
Overall survival patients ≤ 60 years of age
Patients 61–65 years of age
Second line therapy
Patients ≤ 60 years of age
Patients 61–65 years of age
Influence of CR versus non CR after ASCT on survival parameters
Median Overall Survival (Months) (95% CI) | Median Time to New Treatment (Months) (95% CI) | |||||
---|---|---|---|---|---|---|
CR1 | Non CR2 | P- value | CR | Non CR | P-value | |
Period 13 (N = 69) | 92.3 (33.1–151.6) | 56.1 (39.1–73.1) | P = 0.04 | 45.4 (7.0–110.3) | 36.6 (31.3–42.0) | P = 0.001 |
Period 24 (N = 107) | Not reacheda | 81.0 (76.1–113.3) | P = 0.001 | 49.7 (8.4–91.0) | 29.4 (25.6–33.2) | P = 0.001 |
Period 1 + 2 (N = 176) | 133.7 (80.6–186.9) | 79.3 (62.2–96.3) | P = 0.001 | 49.7 (19.2–80.1) | 31.3 (25.2–37.3) | P = 0.001 |
Median Overall Survival (Months) (95%CI) | Median Time to New Treatment (Months) (95%CI) | |||||
---|---|---|---|---|---|---|
CR1 | Non CR2 | P- value | CR | Non CR | P-value | |
Period 13 (N = 32) | 59.8 (41.0–78.5) | 52.1 (8.4–95.8) | P = 0.8 (ns) | 28.7 (5.0.-51.4) | 35.7 (14.9–56.5) | P = 0.8 (ns) |
Period 24 (N = 40) | 75.0 (46.3–102.6) | 50.1 (42.1–68.1) | P = 0.2 (ns) | 56.4 (32.4–80.9) | 29.9 (16.4–39.3) | P = 0.02 |
Period 1 + 2 (N = 72) | 68.5 (51.7–85.4) | 52.3 (48.1–56.1) | P = 0.4 | 43.9 (28.7–59.0) | 31.3 (24.3–37.8) | P = 0.04 |